



**Press Release:**

November 4, 2010 10:00 AM EDT

**Jasco Pharmaceuticals was Awarded a Grant under the Patient Protection and Affordable Care Act**

Woburn, MA November 4, 2010 – Jasco Pharmaceuticals, LLC was awarded a grant under the US Government’s Patient Protection and Affordable Care Act (PPACA) of 2010. The grant was related to Jasco Pharma’s novel small molecule Pim inhibitor program intended to develop therapeutics for the treatment of cancer.

“We are excited to receive the grant in recognition that our innovative Pim inhibitor program shows promise to bring forward a novel oncology therapeutic,” said Carmen Baldino, president of Jasco Pharmaceuticals, “This funding will assist in accelerating the development of our program.”

About Jasco Pharmaceuticals

**Jasco Pharmaceuticals, LLC** is a privately held, pre-clinical stage biopharmaceutical company focused on the development of small molecule oncology therapeutics. Jasco was founded with a core expertise in high speed medicinal chemistry providing a launching point for a chemical genomics approach to the discovery of selective protein kinase inhibitors. The company’s vision is to rapidly and effectively develop pre-clinical oncology candidates that are then guided through the clinical development process by means of strategic partnerships.

For more information about Jasco Pharmaceuticals visit [www.jascopharma.com](http://www.jascopharma.com) or call Carmen M. Baldino, Ph.D. at 339-227-6822 Ext. 12.